title: Octreotide acetate-steroid combination therapy for malignant gastrointestinal obstruction.
abstract: OBJECTIVE
  The Aim of this study was to investigate improvements in symptoms caused by gastrointestinal obstruction following administration of octreotide acetate (Sandostatin®) injection through steroid and opioid administration.
  
  
  METHODS
  Patients (n=37) hospitalized with malignant gastrointestinal obstruction were enrolled in the present study. Twenty seven of them were investigated for gastrointestinal symptoms using the Japanese version of the Support Team Assessment Schedule (STAS-J).
  
  
  RESULTS
  Octreotide acetate was administered intravenously to all 27 patients. Out of them, 17 showed a marked response, four a good response, and six no response. The overall response rate was 77.8%. Octreotide acetate with a steroid was administered to 19 patients; 13 showed a marked response, four a good response, and two no response at all. Multiple logistic regression analysis showed that that steroid administration improved the efficacy of octreotide acetate after adjusting for infusion dose (p=0.03).
  
  
  CONCLUSIONS
  Intravenous administration of octreotide acetate with steroid can effectively improve gastrointestinal symptoms due to malignant gastrointestinal obstruction without adverse events.
authors: Department of Digestive Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan. hal-mura@med.kawasaki-m.ac.jp.
authors: Haruaki
authors: H
authors: Murakami
authors: Hideo
authors: H
authors: Matsumoto
authors: Masafumi
authors: M
authors: Nakamura
authors: Toshihiro
authors: T
authors: Hirai
authors: Yoshiyuki
authors: Y
authors: Yamaguchi
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D000305:Adrenal Cortex Hormones; D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide
keywords: Octreotide; intestinal obstruction; palliative care; steroids